Unknown

Dataset Information

Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies.


ABSTRACT:

Background

Phosphodiesterase type 5 inhibitor (PE5i) administration may stimulate the proliferation and survival of melanocytes. However, discrepancies remain regarding the association between PDE5i use and melanoma risk in observational studies in humans.

Aim

To evaluate the association between PDE5i use and melanoma in a meta-analysis.

Materials and methods

Studies were identified by searching the PubMed and Embase databases. A random-effects model was applied to synthesize the data. A stratified study was performed to evaluate the influence of study characteristics on outcomes.

Results

Four prospective cohort studies and three case-control studies with 1,534,615 male participants and 16,053 melanoma cases were incorporated. Patients who received a PDE5i had

SUBMITTER: Han X 

PROVIDER: S-EPMC5804137 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature